Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Revenue (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Revenue for 15 consecutive years, with $37.2 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 33.45% to $37.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $116.6 million through Dec 2025, up 10.24% year-over-year, with the annual reading at $116.6 million for FY2025, 10.24% up from the prior year.
  • Revenue for Q4 2025 was $37.2 million at Gyre Therapeutics, up from $30.6 million in the prior quarter.
  • The five-year high for Revenue was $101.5 million in Q4 2022, with the low at -$4.9 million in Q4 2021.
  • Average Revenue over 5 years is $24.3 million, with a median of $26.1 million recorded in 2024.
  • The sharpest move saw Revenue crashed 341.16% in 2021, then skyrocketed 3039.92% in 2023.
  • Over 5 years, Revenue stood at -$4.9 million in 2021, then surged by 2172.19% to $101.5 million in 2022, then tumbled by 73.25% to $27.1 million in 2023, then rose by 2.67% to $27.9 million in 2024, then skyrocketed by 33.45% to $37.2 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $37.2 million, $30.6 million, and $26.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.